Bilthoven Biologicals is an arm of Serum Institute of India that makes oral polio vax
IPV has been introduced in UIP as part of Global Polio end-game strategy since November 2015 initially in six states, which was expanded across the country by April 2016
Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...
Serum produces AstraZeneca's Covid-19 vaccine under the brand name Covishield in India, and also makes Novavax's protein-based Covid shots
$30 mn invesment will expand company's ability to swiftly supply investigational vaccines for the Global South
Covid cases in India: On Friday, India recorded 640 fresh Covid-19 infections and the number of active cases now stands at 2,997
Indian billionaire Adar Poonawalla has agreed to pay £138 million for Aberconway House, a 1920s home near Hyde Park, in one of the city's most expensive home sales of the year
The partnership between SII and Mylab is focusing on creating a comprehensive ecosystem for TB diagnosis, treatment, and prevention through various interventions
Over the next three years, Pune-based Serum plans to start production of yellow fever and dengue shots for European and American travelers to countries where those diseases are endemic
The World Health Organization has authorised a second malaria vaccine, a decision that could offer countries a cheaper and more readily available option than the world's first shot against the parasitic disease. WHO Director-General Tedros Adhanom Ghebreyesus said the UN health agency was approving the new malaria vaccine based on the advice of two expert groups, recommending its use in children at risk of the disease. As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two, Tedros said. Oxford University developed the new three-dose vaccine with help from the Serum Institute of India. Research suggests it is more than 75 per cent effective and that protection is maintained for at least another year with a booster. Tedros said the shot would cost about USD 2 to USD 4 and could be available in some countries next year if funders agree to buy it. Earlier this year, regulatory authorities in Ghana and Burkina Faso
The R21/Matrix-M malaria vaccine is an easily deployable vaccine that can be manufactured at a mass scale with a modest cost
Kerala has so far confirmed a total of six cases of Nipah infection since the latest outbreak in the Kozhikode district
The government has approved the export of BCG vaccine manufactured by the Serum Institute of India to Canada for immunotherapy to treat bladder cancer, official sources said on Monday. The permission was granted after Prakash Kumar Singh, director, Serum Institute, wrote to the Drugs Controller of India (DCGI) seeking approval to export BCG for immunotherapy to Canada, they said. BCG as immunotherapy is a live freeze-dried preparation derived from attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin). The product is for intravesical instillation and is available from the Serum Institute in 40 mg and 80 mg presentations, the sources said. As part of the therapy, the vaccine is administered into the bladder through a catheter where it stays in the lining of the bladder for a specific duration affecting the cells and fighting cancer without impacting other body parts.
Serum Institute of India (SII) on Wednesday said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation. MenFive has been developed through a 13-year collaboration between Serum and PATH, a global nonprofit, with crucial funding from the UK government's Foreign, Commonwealth and Development Office. WHO prequalification, which ensures a vaccine meets strict international quality, safety, and efficacy standards, was supported by extensive clinical studies in The Gambia, India, and Mali. Importantly, prequalification allows MenFive to be procured by United Nations agencies and Gavi, the vaccine alliance. "As the first conjugate vaccine to safeguard against the five predominant causes of this deadly disease, MenFive offers hope for a future free from annual outbreaks and epidemics in the African meningitis belt," SII CEO Adar Poonawalla said in a statement. The vaccine protects against ...
The total value of the top 500 companies in India declined marginally by 6.4% to Rs 212 trillion from Rs 227 trillion as of October 30,2022.
The Bombay High Court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and directed them to delete it. A single bench of Justice R I Chagla also temporarily restrained them from posting any content against the company. The SII filed a defamation suit in December 2022 seeking damages to the tune of Rs 100 crore from the two individuals and their organisations for allegedly posting erroneous content against the company and its COVID-19 vaccine Covishield. The company had filed an interim application seeking the court to direct the defendants to delete their posts and to restrain them from posting such content pending final disposal of the suit. The High Court, in its interim order on Monday, said it was of the prima facie view the SII has satisfied the contents and accusations made by the two persons were defamatory. The bench noted that SII and its CEO and owner A
The Bombay High Court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and directed them to delete it. A single bench of Justice R I Chagla also temporarily restrained them from posting any content against the company. The SII filed a defamation suit in December 2022 seeking damages to the tune of Rs 100 crore from the two individuals and their organisations for allegedly posting erroneous content against the company and its COVID-19 vaccine Covishield. The high court on Monday in its interim order said it was of the prima facie view that the SII has satisfied that the contents and accusations made by the two persons were defamatory. "I am of the prima facie view that the contents are per se defamatory. The vaccine is not banned. No case is made out by the defendants," the judge said in the interim order. The court will at a later date take up the company's suit
'From our perspective, we have operated with a high band and a lower band model'
The earlier investment by SILS in BBL was at a valuation of $4.9 billion, and the fresh $150-million investment pushes it up at $6 billion
SILS will now make an additional equity investment of $150 million through the conversion of an earlier loan provided to Biocon Pharma into equity in BBL